<DOC>
<DOCNO>EP-0644198</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Alpha-heteroaryloxymethyl ketones as interleukin-1beta converting enzyme inhibitors.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31397	A61K31397	A61K31415	A61K31415	A61K3142	A61K3142	A61K31421	A61K31421	A61K3147	A61K3147	A61K31472	A61K31472	A61K31535	A61K31535	A61K315375	A61K315375	A61K315377	A61K3155	A61K3155	A61K3800	A61K3800	A61P2900	A61P2900	A61P3700	A61P3700	A61P4300	A61P4300	C07D20500	C07D20504	C07D20700	C07D20738	C07D20900	C07D20912	C07D21500	C07D21514	C07D21700	C07D21716	C07D22300	C07D22308	C07D23100	C07D23120	C07D23122	C07D26100	C07D26112	C07D26300	C07D26306	C07D26500	C07D26506	C07D26530	C07D31100	C07D31146	C07D31150	C07D31156	C07D40100	C07D40112	C07D40900	C07D40912	C07D41300	C07D41304	C07D41700	C07D41712	C07D45300	C07D45302	C07D47100	C07D47104	C07K500	C07K502	C07K506	C07K5062	C07K5078	C07K508	C07K5083	C07K509	C07K5097	C12N999	C12N999	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C07K	C12N	C12N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K38	A61K38	A61P29	A61P29	A61P37	A61P37	A61P43	A61P43	C07D205	C07D205	C07D207	C07D207	C07D209	C07D209	C07D215	C07D215	C07D217	C07D217	C07D223	C07D223	C07D231	C07D231	C07D231	C07D261	C07D261	C07D263	C07D263	C07D265	C07D265	C07D265	C07D311	C07D311	C07D311	C07D311	C07D401	C07D401	C07D409	C07D409	C07D413	C07D413	C07D417	C07D417	C07D453	C07D453	C07D471	C07D471	C07K5	C07K5	C07K5	C07K5	C07K5	C07K5	C07K5	C07K5	C07K5	C12N9	C12N9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Disclosed are compounds, compositions and methods for 
inhibiting interleukin - 1β protease activity, the compounds having the 

formula (I) defined herein. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
STERLING WINTHROP INC
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
AWAD MOHAMED M A C O STERLING
</INVENTOR-NAME>
<INVENTOR-NAME>
CHATURVEDULA PRASAD
</INVENTOR-NAME>
<INVENTOR-NAME>
DOLLE ROLAND E
</INVENTOR-NAME>
<INVENTOR-NAME>
GRAYBILL TODD L C O STERLING W
</INVENTOR-NAME>
<INVENTOR-NAME>
HOYER DENTON W C O STERLING WI
</INVENTOR-NAME>
<INVENTOR-NAME>
PROUTY CATHERINE P
</INVENTOR-NAME>
<INVENTOR-NAME>
ROSS TINA M C O STERLING WINTH
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIDT STANLEY J C O STERLING
</INVENTOR-NAME>
<INVENTOR-NAME>
SINGH JASBIR
</INVENTOR-NAME>
<INVENTOR-NAME>
SPEIER GARY J C O STERLING WIN
</INVENTOR-NAME>
<INVENTOR-NAME>
WHIPPLE DAVID A
</INVENTOR-NAME>
<INVENTOR-NAME>
AWAD, MOHAMED M.A., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
CHATURVEDULA, PRASAD, C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
DOLLE, ROLAND E., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
GRAYBILL, TODD L., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
HOYER, DENTON W., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
PROUTY, CATHERINE P., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
ROSS, TINA M., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIDT, STANLEY J., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
SINGH, JASBIR, C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
SPEIER, GARY J., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
<INVENTOR-NAME>
WHIPPLE, DAVID A., C/O STERLING WINTHROP INC.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
This invention relates to a series of novel amino acid, di- and 
polypeptide analogs which exhibit selective inhibition of interleukin-1β-converting 
enzyme, to compositions containing the novel amino acid 
analogs and methods for therapeutic utility. More particularly, the 
interleukin-1β-converting enzyme inhibitors described in this invention 
comprise novel α-substituted methyl ketones which possess particular 
utility in the treatment of inflammatory and immune-based diseases of 
lung, central nervous system, and connective tissues. Interleukin-1β protease (also known as interleukin-1β-converting 
enzyme or ICE) is the enzyme responsible for processing of the 
biologically inactive 31 kD precursor IL-1β to the biologically active 
17 kD form (Kostura, M.J.; Tocci, M.J.; Limjuco, G.; Chin, J.; Cameron, P.; 
Hillman, A.G.; Chartrain, N.A.; Schmidt, J.A. Proc. Nat. Acad. Sci.. 1989, 
86, 5227-5231 and Black, R.A.; Kronheim, S.R.; Sleath, P.R. FEBS Let., 
1989, 247, 386-391). In addition to acting as one of the body's early 
responses to injury and infection, IL-1β has also been proposed to act 
as a mediator of a wide variety of diseases, including rheumatoid 
arthritis, osteoarthritis, inflammatory bowel disease, sepsis, and acute 
and chronic myelogenous leukemia (Dinarello, C.A.; Wolff, S.M., 
New Engl. J. Med., 1993, 328, 106). The naturally occurring IL-1β 
receptor antagonist has been used to demonstrate the intermediacy of 
IL-1β in a number of human diseases and animal models 
(Hannum, C.N.; Wilcox, C.J.; Arend, W.P.; Joslin, G.G.; Dripps, D.J.; 
Heimdal, P.L.; Armes, L.G.; Sommer, A.; Eisenberg, S.P.; 
Thompson, R.C., Nature, 1990, 343, 336-340; Eisenberg, S.P.; 
Evans, R.J.; Arend, W.P.; Verderber, E.; Brewer, M.T.; Hannum, C.H.; 
Thompson, R.C., Nature 1990, 343, 341-346; Ohlsson, K.; Bjork, P.; 
Bergenfeldt, M.; Hageman, R.; Thompson, R.C., Nature, 1990, 348, 
550-552; and Wakabayashi, G., GASEB, 1991, 338-343). The specific 
role of IL-1β in inflammation and immunomodulation is supported by the 
recent observation that the cowpox virus employs an inhibitor of ICE to 
suppress the inflammatory response of its host (Ray, C.A. et al, Cell, 
1992, 69, 597-604).  The present invention also relates to the modulation of 
processing of IL-1β for the treatment of rheumatoid arthritis. Levels of 
IL-1β are known to be elevated in the synovial fluid of patients with the 
disease. Additionally, IL-1β stimulates the synthesis of enzymes 
believed to be involved in inflammation, such as collagenase and
</DESCRIPTION>
<CLAIMS>
A compound of the formula (I) or a pharmaceutically 
acceptable salt thereof: 

 
wherein: 

   n is 0 - 4; 
   Y is 

 
and when R₃ is OH, then Y can also be 

 
   R₂ is H or deuterium; 

   R₃ is OH, OR₆, NR₆OR₇ or NR₆R₇, 
where R₆ and R₇ are independently H, alkyl, aralkyl, heteroaralkyl, aryl 

or heteroaryl; 
   R₄ is H or alkyl; 

   R₅ is H, alkyl, alkenyl, aryl, heteroaryl, aralkyl, heteroaralkyl, 
aralkenyl, heteroaralkenyl, hydroxy, alkoxy, 2-(alkyoxy)ethoxy, 

2-(alkyoxy)aminoethyl, 2-(alkyoxy)-N-alkylaminoethyl, 
aralkoxy, heteroaralkoxy, alkylacyloxy, aralkylacyloxy, 

heteroaralkylacyloxy, aracyloxy, heteroaracyloxy, aryloxyalkylacyloxy, 
heteroaryloxyalkylacyloxy, alkylacyl, aralkylacyl, 

 
heteroaralkylacyl, alkylacylamino, aralkylacylamino, heteroaralkylacylamino, 

aracylamino, heteroaracylamino, aryloxyalkylacylamino, 
heteroaryloxyalkylacylamino, alkyloxyalkylacylamino, 

alkoxyacylamino, aralkoxyacylamino, heteroaralkoxyacylamino, 
aracyl, heteroaracyl, aryloxyalkylacyl, heteroaryloxyalkylacyl, 

halo, haloalkyl, guanidino, mono- and dialkylguanidino, 
mono- and di-aralkylguanidino, mono- and di-heteroaralkylguanidino, 

alkylacylguanidino, aralkylacylguanidino, 
heteroaralkylguanidino, aracylguanidino, heteroarylguanidino, 

amidino, mono- and di-alkylamidino, mono- and diaralkylamidino, 
mono- and di-heteroaralkylamidino, amino, mono- and dialkylamino, 

mono- and di-aralkylamino, mono- and di-heteroaralkylamino, 
carboxy, alkylcarboxy, carbalkoxy, carbaralkoxy, 

carbheteroaralkoxy, carbalkoxyalkenyl, carboxamido, mono- and 
dialkylcarboxamido, mono- and diarcarboxamido, mono and diheteroarcarboxamido, 

mono- and di-aralkylcarboxamido, monoand 
di-heteroaralkylcarboxamido, thio, alkylthio, arylthio, heteroarylthio, 

aralkylthio, heteroaralkylthio, sulfonamido, mono- and dialkylsulfonamido, 
mono- and di-aralkylsulfonamido, mono- and 

di-heteroaralkylsulfonamido, morpholinosulfonamido, alkylsulfonyl, 
aralkylsulfonyl, heteroaralkylsulfonyl, arylsulfonyl, 

heteroarylsulfonyl, nitro, cyano, N-morpholinoalkyl, 
N-m
orpholinoalkoxy, N-morpholinoaralkyl, N-morpholinoaralkoxy, 
N-morpholinoheteroaralkyl, N-morpholinoheteroaralkoxy, 

N-mono and N,N-dialkylaminoalkyl and N-mono- and 
N,N-dialkylaminoethoxy, quinuclidinylamino, quinuclidinyloxy, 

quinuclidinocarbonyl or ureido; 
   HET is a heteroaryl; 

   AA is independently selected from the group consisting of (a) and 
(b) where group (a) is defined as an amino acid of formula II: 


 
where R₆ and R₇ are defined as above and R₁₁ is (CR₆R₇)₀₋₆-R₁₂ 

where R₁₂ is designated as either an aryl, heteroaryl or a radical 
optionally selected from R₅ wherein R₅, R₆, R₇ are defined previously; 

and group (b) is selected from the group consisting of: 
 

where W and X are optionally CH₂, O, S, or NR₆; and 
R₁ is R₁₂-CO- or R₁₂SO₂-, 

where R₁₂ is as previously defined. 
A compound according to claim 1 wherein HET is a pyrazole of 
formula (III) 

 
wherein R₈, R₉ and R₁₀ are independently aryl, heteroaryl, or a radical 

optionally selected from R₅; and where R₉ and R₁₀ taken together may 
be aryl, heteroaryl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. 
A compound according to claim 1 selected from the group 
consisting of: N-[4-(N,N-Dimethylaminomethyl)]
benzoyl-L-valine-L-aspartic 
acid 5-(1-phenyl-3-trifluoromethyl)pyrazoyloxymethyl ketone, 

N-Benzyloxycarbonyl-L-aspartic acid 5-(1,3-dimethyl)pyrazolyloxy-methyl 
ketone, 

N-Benzyloxycarbonyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)-pyrazolyloxymethyl 
ketone, 

N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(p-fluorophenyl)-3-methyl)-pyrazolyloxy 
methyl ketone, 

N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(p-nitrophenyl)-3-methyl)-pyrazolyloxymethyl 
ketone and 

N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(p-methoxyphenyl)-3-methyl)pyrazolyloxymethyl 
ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(p-chlorophenyl)-3-methyl)pyrazolyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valine-L-alanine-L-aspartic acid 5-(1-phenyl-3-methyl)pyrazolyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1-phenyl-3-methyl)pyrazolyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(m-chlorophenyl)-3-methyl)-pyrazolyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1-benzyl-3-trifluoromethyl)-pyrazolyloxymethyl 

ketone and 
 

N-Benzyloxycarbonyl-L-valine-L-alanine-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl 
ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-aspartic acid 

5-(1-(m,p-dichlorophenyl)3-methyl)pyrazolyloxy methyl ketone, 
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1-phenyl-3-methyl)-pyrazolyloxy 

methyl ketone, and 
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1-phenyl-3-t-butyl)-pyrazolyloxymethyl 

ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valine-L-aspartic acid 

5-(1-(p-trifluoromethylphenyl)3-methyl)pyrazolyloxymethyl ketone, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(p-methanesulfonylphenyl)-3-trifluoromethyl)pyrazolyloxymethyl 

ketone, 
N-4(N,N-Dimethylaminomethyl)benzoyl-L-valine-L-alanine-L-aspartic 

acid 5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1,3-dimethyl-4-phenyl)-pyrazolyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1-(p-methanesulfonylphenyl)-3-methyl)pyrazolyloxymethyl 

ketone and 
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1,3-dimethyl)-4-phenyl)pyrazolyloxymethyl 

ketone. 
The compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valine-L-aspartic acid 

5-(1-phenyl-3-carbethoxy)pyrazolyloxymethyl ketone, 
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1,3-diphenyl)pyrazolyloxymethyl 

ketone, 
N-Methyl-N-[4-(pyridyl)methyl]
carbamoyl-L-valine-L-alanine-L-aspartic 
acid 5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone, 

N-[4-(Pyridyl)methyl]carbamoyl-L-valine-L-alanine-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone, 
N-Benzyloxycarbonyl-L-valine-L-alanine-D-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl 

ketone and 
 

N-Benzyloxycarbonyl-L-valine-L-aspartic acid 5-(1-p-chlorophenyl3-methyl-4-phenyl)pyrazolyloxymethyl 
ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valine-L-aspartic acid 

5-(1,4-diphenyl-3-methyl)pyrazolyloxymethyl ketone, 
N-3-(piperidinopropionyl)-L-valine-L-alanine-L-aspartic acid 

5-(1-phenyl-3-methyl)pyrazolyloxymethyl ketone, 
N-[4-(morpholinoethoxy)benzoyl)-L-valine-L-alanine-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone, 
N-2-(quinuclidinyl)carbonyl-L-valine-L-alanine-L-aspartic acid 

5(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone, 
N-(3-pyridyl)methoxycarbonyl-L-valine-L-alanine-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone and 
N-(2-pyridyl) methoxycarbonyl-L-valine-L-alanine-L-aspartic acid 

5(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Methyl-N-benzylcarbamoyl-L-valine-L-alanine-L-aspartic 

acid 5(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone, 
N-Methyl-N-[2-(4-pyridyl)ethyl]
carbamoyl-L-valine-L-alanine-L-aspartic 
acid 5(1-phenyl-3-trifluoromethyl)pyrazolyloxymethyl ketone and 

N-(N-Phenylpiperazino)carbonyl-L-valine-L-alanine-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazolyloxy methyl ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valyl-L-2-azetidinyl-L-aspartic 

acid 5(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-Benzyloxycarbonyl-L-prolyl-L-valyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-4-Pyridinylmethyloxycarbonyl-L-valyl-L-prolyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-Benzyloxycarbonyl-L-valyl-L-3,4-dehydroprolyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
1-(Benzyloxy-carbonylamino)cyclopropylcarbonyl-L-prolyl-L-aspartic 

acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(4-N,N-Dimethyl-aminomethyl)benzoylvalylprolyl-L-aspartic acid 

5-(1-phenyl-3-tri-fluoromethyl)-pyrazoloxymethyl ketone, 
 

N-Benzyloxycarbonyl-L-valyl-L-pipecolyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 
ketone, 

N-(4-N-Thiazolinylmethyl)-benzoyl-L-valyl-L-pipecolyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-Benzyloxy-carbonyl-L-t-butylglycinyl-L-pipecolyl-L-aspartic acid 
5-(1-(2-pyridinyl)-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-Benzyloxycarbonyl-L-valyl-D,L-tetrahydroisoquinolyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-(4-Pyridinylmethyl)-L-valyl-L-N-methylalanyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-Methoxycarbonyl-L-(ε-N-benzyloxycarbonyl)lysinyl-L-alanyl-L-aspartic 
acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-Methoxycarbonyl-L-lysinyl-L-alanyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 
ketone, N-Benzyloxycarbonyl-L-valyl-L-t-butylglycinyl-L-aspartic 

acid 5-(1-phenyl-3-trifluoromethyl)-pyrazoloxymethyl 
ketone, 

N-Benzyloxycarbonyl-L-t-butylglycinyl-L-alanyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-Benzyloxycarbonyl-D-alanyl-L-valyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 
ketone, 

N-(4-N-Pyrollodinylmethyl)benzoyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(4-(N-Methylpiperizyl)methyl)benzoyl-L-valyl-L-alanyl-D,L-aspartic 

acid 5(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(4-(N-Thiazolidinylmethyl)benzoyl-L-valyl-L-alanyl-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-Benzoyl-L-valyl-L-alanyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-(4-N,N-Dimethylamino-ethoxy)benzoyl-L-valyl-L-alanyl-L-aspartic 

acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-4-Thiomethylbenzoyl-L-valyl-L-alanyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-4-(N,N-Diethylaminomethyl)-benzoyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-4-(2,6-Dimethylpyridinyl)methoxycarbonyl-L-valyl-L-alanyl-L-aspartic 

acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
 

N-4-(N-Morpholinylmethyl)benzoyl-L-valyl-L-alanyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone and 

N-3-(N,N-Dimethylaminomethyl)benzoyl-L-valyl-L-alanyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-3-(1-Naphthyl)propionyl-L-valyl-L-aspartic acid 

5-(1-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-3(4-Quinolinyl)propionyl-L-valyl-L-aspartic acid 5-(1-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-3-(3-Benzothienyl)propionyl-L-valyl-L-aspartic acid 5-(1-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-(4-Methylsulfenyl)benzoyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(4-N-Morpholinylethoxy)benzoyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(S-2-Hydroxy-3-methyl)propionyl-L-valyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-(3-N-Piperidinyl)propionyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(N-Phenyl-piperazinyl)formyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-(S-1-Hydroxy-2-phenyl)propionyl-L-valyl-L-aspartic acid 5(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valyl-L-aspartic acid 5(1-(4-(7-chloro)-quinolinyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valyl-L-alanyl-L-aspartic acid 

5-(1-(4-(7-chloro)quinolinyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 
N-Benzyloxycarbonyl-L-valyl-L-alanyl-L-aspartic acid 5-(1-(4-chloro)-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone Ethyl ester, 
N-Benzyloxycarbonyl-L-valyl-L-alanyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 

ketone Ethyl ester, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1-(4-fluorophenyl)-3-methyl)-pyrazoloxymethyl 

ketone Methyl ester, 
N-Benzyloxycarbonyl-L-aspartic acid 5-(1-phenyl-3-methyl)pyrazoloxy-methyl 

ketone Benzyl ester, 
 

N-Benzyloxycarbonyl-L-valyl-L-aspartic acid 5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl 
ketone lsopropyl ester, 

N-Benzyloxycarbonyl-L-aspartic acid 5-(1-phenyl-3-methyl)pyrazoloxymethyl 
ketone 2-Aminoethyl ester, 

N-Benzyloxycarbonyl-L-aspartic hydroxamic acid 2,6-dichlorobenzoyloxymethyl 
ketone, 

N-(4-(1-Carboxyethyl))benzoyl-L-valyl-L-alanyl-L-aspartic acid 
5-(1-phenyl-3-trifluoromethyl)pyrazoloxymethyl ketone, 

N-Benzyl-oxycarbonyl-L-valyl-L-alanyl-L-aspartic acid 5-(1-(5-chloro-2-pyridinyl-3-trifluoromethyl)pyrazoloxymethyl 
ketone and 

N-(1-Naphthyl))ethoxycarbonyl-L-valyl-L-aspartic acid 5-(1-(4-chlorophenyl)-3-trifluoromethyl)pyrazoloxymethyl 
ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valine-L-aspartic acid 3-phenylcoumarinoloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-aspartic acid coumarinoloxymethyl ketone, 

N-Benzyloxycarbonyl-L-aspartic acid thiocoumarinoloxymethyl ketone, 
N-Benzyloxycarbonyl-L-aspartic acid phenylcoumarinoloxymethyl 

ketone and 
N-Benzyloxycarbonyl-L-valine-L-alanine-aspartic acid 3-phenyl-coumarinoloxymethyl 

ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valine-D,L-aspartic acid 

4-(3-phenyl)isoxazoloxymethyl ketone, 
N-Benzyloxycarbonyl-L-valine-D,L-aspartic acid 3-(5-methyl-4-phenyl)-isoxazoloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valine-L-alanine-L-aspartic acid 5-(3-phenyl) 

isoxazoloxymethyl ketone and 
N-Benzyloxycarbonyl-L-valine-L-alanine-L-aspartic acid 

5-[3(4-pyridinyl)]isoxazoloxymethyl ketone. 
A compound according to claim 1 selected from the group 
consisting of: N-Benzyloxycarbonyl-L-valine-D,L-aspartic acid 3-phenyl-tetramoyloxymethyl 

ketone, 
N-Benzyloxycarbonyl-L-valine-D,L-aspartic acid 3-phenyl-N-methyl-tetramoyloxymethyl 

ketone and 
 

N-Benzyloxycarbonyl-L-valine-D,L-aspartic acid 3-phenyl-N-phenyl-tetramoyloxymethyl 
ketone. 
A pharmaceutical composition for inhibiting interleukin-1β 
protease comprising a compound of the formula (I) or a 

pharmaceutically acceptable salt thereof as claimed in any one of the 
preceding claims in a pharmaceutically acceptable carrier. 

16. The use of a compound of formula (I) or a pharmaceutically 
acceptable salt thereof according to any one of claims 1 to 13 or a 

pharmaceutical composition according to claim 15 for the preparation of 
a medicament for inhibiting interleukin-1β protease activity in a mammal 

in need of such treatment. 
</CLAIMS>
</TEXT>
</DOC>
